EMD Serono and Pfizer Inc. announced the FDA has accepted for Priority Review the supplemental Biologics License Application for Bavencio (avelumab) in combination with Inlyta (axitinib) for patients with advanced renal cell carcinoma. The application has been given a target action date in June 2019.
Merck announced new combination and monotherapy data from the company's immuno-oncology research program in genitourinary cancers will be presented at the 2019 Genitourinary Cancers Symposium in San Francisco Feb. 14-16.
The first study of the immunotherapy drug pembrolizumab as the initial treatment for patients with Merkel cell carcinoma reports better responses and longer survival than expected with conventional chemotherapy, the researchers said.
University of Maryland School of Medicine surgeons have identified a group of lymph nodes in the chest that appear highly significant in predicting the prognosis for patients with malignant pleural mesothelioma.
Pfizer Inc. and Astellas Pharma Inc. announced results from the phase III ARCHES trial in men with metastatic hormone-sensitive prostate cancer.
Bristol-Myers Squibb Co. announced new results from the phase III CheckMate-214 study, showing that therapy with Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) continued to demonstrate long-term survival benefits in patients with previously untreated advanced or metastatic renal cell carcinoma.
A UCLA-led study suggests that for people with recurrent glioblastoma, administering an immunotherapy drug before surgery could help prolong their lives.
The black-white gap has closed considerably over the past several decades, a new report finds.
The American Cancer Society Cancer Action Network released a report that report examines the growing burden of cervical cancer in low- and middle-income countries around the world.
Caryn Lerman was named director at USC Norris Comprehensive Cancer Center, effective March 15.
